Gilead 0124: A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Study Status
Open to Enrollment
Study Description
This clinical trial is for men and women with indolent non-Hodgkin lymphoma (iNHL) that has been previously treated. The study is evaluating an experimental drug called idelalisib (also called GS-1101, previously CAL-101) in combination with a standard drug, rituximab.
The purpose of the study is to evaluate the effectiveness of idelalisib combined with rituximab in treating iNHL. Idelalisib blocks some of the cell functions that cause iNHL to grow and survive. Rituximab is FDA-approved for treating iNHL. It is possible that giving rituximab together with idelalisib may have more activity against iNHL than giving rituximab alone.
- Group 1: rituximab + idelalisib
- Group 2: rituximab + placebo (a tablet that looks like idelalisib but contains no medicine)
Participants have a 2:1 chance of being assigned to Group 1 vs. Group 2, meaning participants are twice as likely to receive rituximab and idelalisib. Participants in both treatment groups will receive 8 rituximab infusions over 36 weeks. Participants will take idelalisib tablets by mouth twice daily.
Participants will continue on idelalisib/placebo as long as they are responding to therapy and not experiencing unacceptable side effects.
Disease Status and/or Stage
Previously Treated Indolent non-Hodgkin Lymphoma
Sponsor
Gilead
Key Eligibility
- Men and women age 18 and older
- B-cell indolent non-Hodgkin lymphoma (iNHL)
- Have received prior therapy containing anti-CD20 antibody
- iNHL is not refractory to rituximab
- Detailed eligibility reviewed when you contact the study team
Principal Investigator
Contact
- Amelyn Rodriguez, RN
- (212) 746-1362
- [email protected]
Protocol ID
Gilead 0124
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]